140 related articles for article (PubMed ID: 31028057)
21. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
Chiba M; Hensleigh M; Lin JH
Biochem Pharmacol; 1997 Apr; 53(8):1187-95. PubMed ID: 9175724
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
Chan TS; Scaringella YS; Raymond K; Taub ME
Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
[TBL] [Abstract][Full Text] [Related]
23. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
24. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys.
Jin L; Chen IW; Chiba M; Lin JH
Xenobiotica; 2003 Jun; 33(6):643-54. PubMed ID: 12851040
[TBL] [Abstract][Full Text] [Related]
25. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
26. Effects of metronidazole on midazolam metabolism in vitro and in vivo.
Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):555-9. PubMed ID: 11151744
[TBL] [Abstract][Full Text] [Related]
27. Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro.
Keubler A; Weiss J; Haefeli WE; Mikus G; Burhenne J
Drug Metab Dispos; 2012 Jun; 40(6):1178-82. PubMed ID: 22415932
[TBL] [Abstract][Full Text] [Related]
28. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
29. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
30. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
31. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Shibata Y; Takahashi H; Chiba M; Ishii Y
Drug Metab Pharmacokinet; 2008; 23(5):328-39. PubMed ID: 18974610
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro metabolism of indinavir in primates--a unique stereoselective hydroxylation in monkey.
Chiba M; Nishime JA; Neway W; Lin Y; Lin JH
Xenobiotica; 2000 Feb; 30(2):117-29. PubMed ID: 10718120
[TBL] [Abstract][Full Text] [Related]
33. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects.
Dhuria S; Einolf H; Mangold J; Sen S; Gu H; Wang L; Cameron S
J Clin Pharmacol; 2013 Jun; 53(6):642-53. PubMed ID: 23585187
[TBL] [Abstract][Full Text] [Related]
34. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo glucuronidation of midazolam in humans.
Hyland R; Osborne T; Payne A; Kempshall S; Logan YR; Ezzeddine K; Jones B
Br J Clin Pharmacol; 2009 Apr; 67(4):445-54. PubMed ID: 19371318
[TBL] [Abstract][Full Text] [Related]
36. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
37. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
38. Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.
Tanna RS; Tian DD; Cech NB; Oberlies NH; Rettie AE; Thummel KE; Paine MF
J Pharmacol Exp Ther; 2021 Jan; 376(1):64-73. PubMed ID: 33093187
[TBL] [Abstract][Full Text] [Related]
39. Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors.
Gass RJ; Gal J; Fogle PW; Detmar-Hanna D; Gerber JG
Eur J Clin Pharmacol; 1998; 54(9-10):741-7. PubMed ID: 9923578
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
